The company presented the results at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology in April.
Kemin Industries (Des Moines, IA) says a new study presented in April at the Association for Research in Vision and Ophthalmology annual meeting shows that the company’s Neumentix nootropic ingredient may also support the eyes’ neural tissue.
Kemin’s research partner on the study was the University of Pisa in Italy. At the conference, Rosario Amato, PhD, a postdoctoral research fellow from the University of Pisa, presented data gleaned from the study, which was conducted in a rat model of hypertensive glaucoma.
“Our findings emphasized the intraocular pressure–independent antioxidant and neuroprotective effects of Neumentix,” said Amato in a press release.
Massimo Dal Monte, the study’s principal investigator and a professor at the University of Pisa, added, “The research substantiates the role of oxidative stress and inflammation in driving neurodegeneration in retinal ganglion cells, but also demonstrates the potential to counteract these drivers with nutritional strategies.”
According to Kemin’s press release, “The study findings validated Neumentix’s expanded mechanisms of action that are effective for neural tissues beyond the brain. Results indicated the Neumentix, Kemin’s natural spearmint (Mentha spicata L.) extract, sourced from patented plants and characterized by its phenolic complex, works to counteract common degenerative pathways in the eyes and brain.”